QuidelOrtho (NASDAQ:QDEL) Shares Down 7.5% – Time to Sell?

Shares of QuidelOrtho Corporation (NASDAQ:QDEL) dropped 7.5% during mid-day trading on Monday . The stock traded as low as $12.63 and last traded at $12.6450. Approximately 499,750 shares changed hands during mid-day trading, a decline of 73% from the average daily volume of 1,825,782 shares. The stock had previously closed at $13.67.

Wall Street Analyst Weigh In

QDEL has been the topic of several analyst reports. UBS Group reissued a “neutral” rating and set a $12.00 target price on shares of QuidelOrtho in a research report on Thursday, May 7th. Jefferies Financial Group cut QuidelOrtho from a “buy” rating to a “hold” rating and reduced their price target for the stock from $35.00 to $12.50 in a research report on Thursday, May 7th. Wall Street Zen downgraded QuidelOrtho from a “hold” rating to a “sell” rating in a research note on Saturday. Zacks Research raised QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Monday, June 15th. Finally, Citigroup cut their price objective on QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Four analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $14.88.

QuidelOrtho Stock Down 9.5%

The business’s 50 day moving average is $12.80 and its 200-day moving average is $20.77. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43. The firm has a market capitalization of $843.85 million, a price-to-earnings ratio of -0.69 and a beta of 0.77.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). The firm had revenue of $619.80 million for the quarter, compared to the consensus estimate of $665.23 million. QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The firm’s revenue was down 10.5% on a year-over-year basis. During the same quarter last year, the company earned $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Equities analysts anticipate that QuidelOrtho Corporation will post 1.83 EPS for the current fiscal year.

Institutional Trading of QuidelOrtho

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Global Retirement Partners LLC increased its holdings in QuidelOrtho by 3,691.7% in the 4th quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock valued at $26,000 after buying an additional 886 shares during the period. Camelot Portfolios LLC bought a new position in shares of QuidelOrtho during the 4th quarter worth about $29,000. Hantz Financial Services Inc. lifted its holdings in shares of QuidelOrtho by 50.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after acquiring an additional 362 shares during the period. Larson Financial Group LLC boosted its position in shares of QuidelOrtho by 322.2% during the 3rd quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after acquiring an additional 1,015 shares in the last quarter. Finally, Leonteq Securities AG boosted its position in shares of QuidelOrtho by 555.2% during the 1st quarter. Leonteq Securities AG now owns 3,466 shares of the company’s stock valued at $57,000 after acquiring an additional 2,937 shares in the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.